



Universiteit  
Leiden  
The Netherlands

**Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma (vol 126, pg 93, 2020)**

Decaudin, D.; Leitz, E.F.D.; Nemat, F.; Tarin, M.; Naguez, A.; Zerara, M.; ... ; Alsafadi, S.

**Citation**

Decaudin, D., Leitz, E. F. D., Nemat, F., Tarin, M., Naguez, A., Zerara, M., ... Alsafadi, S. (2023). Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma (vol 126, pg 93, 2020). *European Journal Of Cancer*, 184, 199-199. doi:10.1016/j.ejca.2023.02.004

Version: Publisher's Version  
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)  
Downloaded from: <https://hdl.handle.net/1887/3715547>

**Note:** To cite this publication please use the final published version (if applicable).



Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.ejcancer.com](http://www.ejcancer.com)



## Corrigendum

# Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]



Didier Decaudin <sup>a,b,1</sup>, Estelle Frisch Dit Leitz <sup>c,1</sup>, Fariba Nemati <sup>a,1</sup>, Malcy Tarin <sup>c</sup>, Adnan Naguez <sup>a</sup>, Mohamed Zerara <sup>a</sup>, Benjamin Marande <sup>c</sup>, Raquel Vivet-Noguer <sup>c</sup>, Ensar Halilovic <sup>d</sup>, Claire Fabre <sup>d</sup>, Aart Jochemsen <sup>e</sup>, Sergio Roman-Roman <sup>c</sup>, Samar Alsafadi <sup>c,\*</sup>

<sup>a</sup> Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France

<sup>b</sup> Department of Medical Oncology, Institut Curie, Paris, France

<sup>c</sup> Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France

<sup>d</sup> Novartis Institutes for Biomedical Research, Cambridge, MA, USA

<sup>e</sup> Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands

The authors regret that the acknowledgements section of the published paper was incomplete and should include the following statement:

Raquel Vivet-Noguer was supported by the Institut Curie 3-i PhD Program under Marie Skłodowska-Curie Grant Agreement No 666003.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejca.2019.12.012>.

\* Corresponding author:

E-mail addresses: [samar.alsafadi@curie.fr](mailto:samar.alsafadi@curie.fr), [samaralsafadi@yahoo.com](mailto:samaralsafadi@yahoo.com) (S. Alsafadi).

<sup>1</sup> Joint first co-author.

<https://doi.org/10.1016/j.ejca.2023.02.004>

0959-8049/© 2023 The Author(s). Published by Elsevier Ltd. All rights reserved.